Literature DB >> 10839726

Chlamydia pneumoniae and other risk factors for atherosclerosis.

M Leinonen1.   

Abstract

Seroepidemiologic studies have provided information on the association of Chlamydia pneumoniae with the classical risk factors of coronary heart disease (CHD). C. pneumoniae infections are more common in smokers than in nonsmokers, suggesting that smoking predisposes to the development of chronic infection. Infections may also affect lipid metabolism. In persons with acute pneumonia caused by C. pneumoniae, high-density lipoprotein (HDL) values are lower and triglyceride values higher than seen in pneumonia caused by viruses and other bacteria. Furthermore, chronic C. pneumoniae infection is associated with elevated triglyceride and lowered HDL levels in healthy Finnish men. Recent studies also suggest that chronic C. pneumoniae infection considerably enhances the effect of the metabolic syndrome on the CHD risk. Thus, known CHD risk factors may be partly explained by their association with chronic C. pneumoniae infection. Further studies are needed to elucidate the pathogenetic mechanisms underlying these associations.

Entities:  

Mesh:

Year:  2000        PMID: 10839726     DOI: 10.1086/315624

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  3 in total

1.  Presence of Chlamydia pneumoniae in patients with and without atherosclerosis.

Authors:  E Podsiadły; J Przyłuski; A Kwiatkowski; M Kruk; M Wszoła; R Nosek; W Rowiński; W Ruzyłło; S Tylewska-Wierzbanowska
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-08       Impact factor: 3.267

2.  Association of Chlamydia pneumoniae infection with HLA-B*35 in patients with coronary artery disease.

Authors:  Anil Palikhe; Marja-Liisa Lokki; Pekka Saikku; Maija Leinonen; Mika Paldanius; Mikko Seppänen; Ville Valtonen; Markku S Nieminen; Juha Sinisalo
Journal:  Clin Vaccine Immunol       Date:  2007-11-07

3.  A novel transport mechanism for MOMP in Chlamydophila pneumoniae and its putative role in immune-therapy.

Authors:  Francis O Atanu; Ernesto Oviedo-Orta; Kimberly A Watson
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.